Complementary and Integrative Medicine to Reduce Adverse Effects of Anticancer Therapy

Rossi, Elio; Noberasco, Cristina; Picchi, Marco; Stefano, Mariella Di; Rossi, Antonella Russo; Nurra, Linda; Ventura, Leonardo

doi:10.1089/acm.2018.0143

Cited by 19 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, still unclear is the clinical severity of the side effects of SCD1 inhibitors. The vast majority of commonly used chemotherapeutic agents cause a wide spectrum of severe adverse symptoms, including gastrointestinal disorders, neuropathy, depression, leukopenia, and heart failure [178,179,180]. Thus, the potential benefits of the anti-cancer properties of SCD1 inhibitors may outweigh their risk of side effects, which may not necessarily be more severe than the consequences of ineffective cancer treatment.…”

Section: Perspectives Of Scd1 Inhibitors In Anticancer Therapymentioning

confidence: 99%

Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer

Tracz-Gaszewska

Dobrzyń

2019

Cancers

165

149

View full text Add to dashboard Cite

A distinctive feature of cancer cells of various origins involves alterations of the composition of lipids, with significant enrichment in monounsaturated fatty acids. These molecules, in addition to being structural components of newly formed cell membranes of intensely proliferating cancer cells, support tumorigenic signaling. An increase in the expression of stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids to ∆9-monounsaturated fatty acids, has been observed in a wide range of cancer cells, and this increase is correlated with cancer aggressiveness and poor outcomes for patients. Studies have demonstrated the involvement of SCD1 in the promotion of cancer cell proliferation, migration, metastasis, and tumor growth. Many studies have reported a role for this lipogenic factor in maintaining the characteristics of cancer stem cells (i.e., the population of cells that contributes to cancer progression and resistance to chemotherapy). Importantly, both the products of SCD1 activity and its direct impact on tumorigenic pathways have been demonstrated. Based on these findings, SCD1 appears to be a significant player in the development of malignant disease and may be a promising target for anticancer therapy. Numerous chemical compounds that exert inhibitory effects on SCD1 have been developed and preclinically tested. The present review summarizes our current knowledge of the ways in which SCD1 contributes to the progression of cancer and discusses opportunities and challenges of using SCD1 inhibitors for the treatment of cancer.

show abstract

Section: Perspectives Of Scd1 Inhibitors In Anticancer Therapymentioning

confidence: 99%

Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer

Tracz-Gaszewska

Dobrzyń

2019

Cancers

165

149

View full text Add to dashboard Cite

show abstract

“…It can decrease the appetite leading to reduced oral intake and weight loss. Zinc supplements have shown to be useful to improve the dysgeusia in a few studies (17)(18)(19).…”

Section: Dental Care For Hnc Patientsmentioning

confidence: 99%

The Multidisciplinary Team (MDT) Approach and Quality of Care

et al. 2020

View full text Add to dashboard Cite

The core function of a multidisciplinary team (MDT) is to bring together a group of healthcare professionals from different fields in order to determine patients' treatment plan. Most of head and neck cancer (HNC) units are currently led by MDTs that at least include ENT and maxillofacial surgeons, radiation and medical oncologists. HNC often compromise relevant structures of the upper aerodigestive tract involving functions such as speech, swallowing and breathing, among others. The impairment of these functions can significantly impact patients' quality of life and psychosocial status, and highlights the crucial role of specialized nurses, dietitians, psycho-oncologists, social workers, and onco-geriatricians, among others. Hence, these professionals should be integrated in HNC MDTs. In addition, involving translational research teams should also be considered, as it will help reducing the existing gap between basic research and the daily clinical practice. The aim of this comprehensive review is to assess the role of the different supportive disciplines integrated in an MDT and how they help providing a better care to HNC patients during diagnosis, treatment and follow up.

show abstract

“…1 Many cancer patients around the world have recourse to traditional, complementary, and integrative medicine to improve their well-being and check the symptoms of adverse effects of conventional therapies. [2][3][4][5][6][7] Indeed, 8 of the 10 hospitals rated the best in 2019 8 provide such therapies, including adjuvant homeopathic treatment, with satisfactory outcomes. [9][10][11][12][13] In contrast, there are almost no reports of homeopathic treatment of disease itself, and those available basically describe single cases or small series.…”

Section: Introductionmentioning

confidence: 99%

Homeopathy in Experimental Cancer Models: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Background Complementary and alternative medicine, including homeopathy, is widely used to improve well-being among cancer patients and reduce adverse effects of conventional treatment. In contrast, there are few studies on the use of homeopathic medicines to treat the disease itself. Yet, evidence of possible effectiveness of homeopathic high dilutions in experimental cancer models has been published during the past 20 years. Aim The aim of the study was to perform a systematic review of fundamental research studies on homeopathic high dilutions in cancer. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, we conducted a literature search in the database PubMed for original publications, from 2000 to 2018 and in English, on in vitro and in vivo experimental cancer models testing homeopathic high dilutions. Results Twenty-three articles met the inclusion criteria—14 in vitro, eight in vivo, and one in vitro plus in vivo experimental models. Most studies were from India. Research prominently focused on cytotoxic effects involving apoptotic mechanisms. Intrinsic aspects of homeopathy should be considered in experimental designs to emphasize the specificity of such effects. Conclusion Fundamental research of homeopathy in cancer is still at an early stage and has mainly been performed by a few groups of investigators. The results point to an interference of well-selected homeopathic medicines with cell cycle and apoptotic mechanisms in cancer cells. However, these findings still need independent reproduction.

show abstract

Complementary and Integrative Medicine to Reduce Adverse Effects of Anticancer Therapy

Cited by 19 publications

References 19 publications

Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer

Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer

The Multidisciplinary Team (MDT) Approach and Quality of Care

Homeopathy in Experimental Cancer Models: A Systematic Review

Contact Info

Product

Resources

About